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ABSTRACT
Background: Percutaneous renal sympathetic denervation was 
developed as an adjunct method to treat clinical conditions 
associated to sympathetic hyperactivity. Percutaneous renal 
sympathetic denervation increases the renal blood flow and 
reduces vasoconstriction. The effects of percutaneous renal 
sympathetic denervation in renal artery diameter have not 
been reported. Our objective was to evaluate such effects by 
quantitative angiography. Methods: Prospective, observational, 
study including consecutive patients undergoing percutaneous 
renal sympathetic denervation. Results: Thirty-one patients 
were selected, 21 were submitted to percutaneous renal sym-
pathetic denervation to control resistant arterial hypertension 
and 10 to control refractory ventricular arrhythmias. Seventeen 
patients did not perform renal arteriography in the follow-up 
due to clinical contraindications or because they did not 
complete the 6-month period established by the protocol.
In addition, one patient performed a unilateral percutaneous 
renal sympathetic denervation and was also excluded from 
this analysis. Therefore, 52 renal angiographies (26 pairs) of 
13 patients were analyzed. Mean maximal diameter of the 
right renal artery before the procedure was 4.54 ± 0.21 mm 
and increased to 5.2 ± 0.44 mm at 6 months (p  =  0.01). 
Likewise, there was a significant increase in the diameter of 
the left renal artery at 6 months of follow-up, increasing from 
4.37 ± 0.42 to 5.23 ± 0.77 mm (p = 0.02). Conclusions: The 
results of this analysis illustrate the significant increment in 
renal artery diameter after percutaneous renal sympathetic 
denervation. Randomized controlled clinical trials are required 
to consolidate our observations.
DESCRIPTORS: Hypertension. Drug resistance. Renal artery. 
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RESUMO
Efeitos da Denervação Simpática Renal no  
Diâmetro da Artéria Renal Avaliados  
Pela Angiografia Quantitativa
Introdução: A denervação simpática renal percutânea surgiu 
como método adjunto no controle de condições clínicas as-
sociadas à hiperatividade simpática. Ela resulta em aumento 
do fluxo sanguíneo renal e em redução da vasoconstrição. Os 
efeitos da denervação simpática renal percutânea no diâmetro 
da artéria renal ainda não foram descritos. Nosso objetivo 
foi avaliar tais efeitos por meio da angiografia quantitativa. 
Métodos: Estudo prospectivo e observacional que incluiu 
pacientes consecutivos submetidos à denervação simpática 
renal percutânea. Resultados: Selecionamos 31 pacientes, 
sendo 21 submetidos à denervação simpática renal per-
cutânea para controle da hipertensão arterial resistente e 10 
para controle de arritmias ventriculares refratárias. Dezessete 
pacientes não realizaram arteriografia renal no seguimento 
por não completarem o período protocolar de 6 meses, ou 
por contraindicação clínica. Adicionalmente, uma paciente 
realizou denervação simpática renal percutânea unilateral, 
sendo também excluída desta análise. Assim, 52 angiografias 
renais (26 pares) de 13 pacientes foram analisadas. A média 
do diâmetro máximo da artéria renal direita, antes do procedi-
mento, foi de 4,54 ±  0,21 mm e aumentou para 5,2 ± 0,44 
mm aos 6 meses (p  =  0,01). Da mesma forma, observou-se 
aumento significativo do diâmetro da artéria renal esquerda 
aos 6 meses de seguimento, ampliando de 4,37 ± 0,42 para 
5,23 ± 0,77 mm (p = 0,02). Conclusões: Os resultados desta 
análise ilustram o incremento significativo dos diâmetros das 
artérias renais após denervação simpática renal percutânea. 
Ensaios clínicos randomizados e controlados são necessários 
para consolidar nossas observações.
DESCRITORES: Hipertensão. Resistência a medicamentos. 
Artéria renal. Simpatectomia. Ablação por cateter. Angiografia.
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A pproximately one billion people suffer from sys-temic arterial hypertension (SAH) worldwide.1 It is well established that an increase in blood 
pressure is associated with an increased risk of cardio-
vascular disease. Conversely, small reductions in blood 
pressure (BP) substantially decrease the rates of stroke, 
coronary artery disease, and heart failure, also denot-
ing a reduction in the number of hospitalizations, their 
related costs, and deaths, as well as an improvement 
in quality of life in patients with SAH.2,3
Based on the knowledge of the importance of 
hyperactivity of the sympathetic autonomic nervous 
system in the pathophysiology of SAH, percutaneous 
renal sympathetic denervation (RSD) has emerged as 
an adjunctive therapeutic strategy in selected groups of 
refractory hypertensive patients.4 Benefits have also been 
observed with this method in other clinical contexts 
associated with chronic hyperactivity of the sympathetic 
nervous system (SNS), such as cardiac arrhythmias,5 
obstructive sleep apnea syndrome,6 heart failure,7 and 
metabolic syndrome.8
Despite the promising initial results of percutaneous 
RSD related to SAH, discrepancies have been observed 
among studies, in large part reflecting the variation 
in the technique used the learning curve, the type of 
device used, and, especially, the different populations 
studied, with a wide variation of the importance of the 
sympathetic system in the genesis of SAH.
Sympathetic activity in the context of percutane-
ous RSD is measured by microneurography and by 
norepinephrine spillover.9 However, although available, 
these procedures are not adopted routinely in clinical 
practice, due to limitations in their execution.
Chronic SNS stimulation progresses with an in-
crease in plasma neurohormones, which in turn results 
in vascular (vasoconstriction, increased thickness, and 
reduced vascular compliance) and heart (development 
of myocardial hypertrophy, ischemia, arrhythmias, and 
heart failure) effects. In kidneys, an increased sympathetic 
activity leads to the activation of the renin-angiotensin-
aldosterone system, increased reabsorption of sodium 
and water, reduction of renal blood flow and glomerular 
filtration rate, ischemia, and renal failure.10
Percutaneous RSD aims to reduce sympathetic ac-
tivity. As a consequence, there is an increase in renal 
blood flow9 and arterial vasodilation.10 In this study; the 
aim was to evaluate the effects of percutaneous RSD 




Thirty-one consecutive patients undergoing per-
cutaneous RSD at the Instituto Dante Pazzanese de 
Cardiologia were selected. The indication for the pro-
cedure was for control of refractory hypertension in 21 
of these patients and for control of refractory ventricular 
arrhythmias in the other ten.
Procedure
In 26 patients, an open-irrigated tip catheter (Ther-
moCool® or Therapy Cool Path®) was used and, in five, 
the dedicated system EnligHTN® (St. Jude Medical Inc®, 
Westford, United States). 
Four to six radiofrequency applications were per-
formed in each renal artery with the irrigated catheter, 
starting at the most distal portion of the vessel, close to 
the bifurcation, toward the aorta, respecting the mini-
mum distance of 5 mm between each application and 
the helical arrangement of them. The detailed technique 
for a percutaneous RSD with an irrigated catheter has 
been described previously elsewhere by our group.11 
Figure 1 shows a case in which six radiofrequency 
applications were conducted in the right renal artery. 
EnligHTN® is a dedicated system for percutaneous RSD, 
designed with the aim of generating better-distributed renal 
artery lesions, and, therefore, four radiofrequency applications 
are performed with a minimal manipulation of the catheter. 
The device consists of a catheter with a basket at its distal 
end, which has four electrodes that sequentially emit the 
radiofrequency. Initially, the device was placed distally in 
the renal artery, wherein a first section of application was 
performed. After this step, the device was collapsed and 
retracted by about 1 cm, for a new application – a total of 
eight applications per treated renal artery were performed. 
The technique outlined for percutaneous RSD with the 
EnligHTN® dedicated system has been described previously 
elsewhere by the present group.12
Quantitative angiography
Of those 31 patients selected, 17 did not undergo 
renal arteriography under the protocol during follow-
up, or because they did not complete the six-month 
period, or due to clinical contraindication. Fourteen 
patients underwent angiography 6 months after percu-
taneous RSD, which allowed for the comparison of this 
examination versus the initial examination performed 
before the ablation. One case was excluded from this 
analysis, because the patient was submitted to ablation 
of only one renal artery. Thus, 52 renal arteriographies 
(26 pairs) from 13 patients were analyzed by quantita-
tive angiography.
The quantitative renal angiography was interpreted 
with the help of QAngio XA software, version 7.3 (Medis 
Medical Imaging Systems BV, Leiden, The Netherlands). 
The maximum diameters of each renal artery were 
measured at three points: proximal, middle and distal 
thirds. The mean measure was calculated automatically 
by the program (Figure 2).
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Continuous variables were expressed as mean and 
standard deviation and compared using Student’s t-test. 
Categorical variables were presented as absolute and 
relative frequencies. For all parameters compared, p-
values   < 0.05 were considered statistically significant. 
Data were analyzed using SPSS®, version 16.0 for 
Windows® (SPSS® Inc., Chicago, Illinois, United States).
RESULTS
Fifty-two renal angiograms were analyzed. The 
mean age was 49 ± 10 years and 11 (84.6%) patients 
were female. The baseline characteristics of all patients 
included in the study are shown in Table 1.
Technical characteristics of the procedure
The volume of contrast used was 87.7 ± 29.7 mL 
and the fluoroscopy time was 21.4 ± 6.6 minutes. 
On average, five applications were performedon each 
renal artery.
Quantitative angiography
Figure 3 exemplifies a quantitative angiography in 
right renal artery before and 6 months after percutane-
ous RSD. 
The length of the left and right renal arteries was 
26.9 ± 8.9 mm and 36.3 ± 7.4 mm, respectively. 
The maximum diameter of the right renal artery 
before the procedure was 4.54 ± 0.21  mm, showing 
an increase to 5.20 ± 0.44 mm at 6 months (p = 0.01). 
Similarly, an increase was observed in the diameter of 
the left renal artery at 6 months of follow-up, which 
changed from 4.37 ± 0.42 mm to 5.23 ± 0.77 mm 
(p =  0.02) (Figure 4).
DISCUSSION
This was the first study which prospectively as-
sessed the effects of percutaneous RSD in the diameter 
of renal arteries. It was observed, using quantitative 
angiography, a significant increase in diameter, probably 
Figure 1 – Sequential radiofrequency applications initiated in the distal segment of the right renal artery. The catheter is pulled and rotated after 
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through two mechanisms: (1) increased renal blood flow 
and (2) decreased vasoconstriction, both as a result of 
blocking or reduction of sympathetic activity, caused 
by percutaneous RSD. 
Coronary angiography is the gold standard of imaging 
for analysis of coronary anatomy; this technique provides 
definition of the extent and precise location of coronary 
artery disease. A well-performed coronary angiography 
requires a thorough knowledge of anatomy, including 
its variations, and a protocol for systematic acquisition 
of sequential images that allows the visualization of all 
coronary segments, especially in areas with overlapping 
vessels, bifurcations, and tortuous anatomy. Late lumen 
loss, a procedure applied for years for quantification 
of neointimal hyperplasia, has become one of the 
most sensitive and surgeon-independent angiographic 
evaluations of the effectiveness of coronary stents, 
both for drug-eluting devices or other types. Classi-
cally defined as the difference between the minimum 
lumen diameter (MLD) obtained immediately after the 
procedure (final MLD) and the MLD obtained during 
follow-up, late lumen loss is an angiographic measure 
of the absolute degree of vascular restenosis, different 
from the binary restenosis calculation.13,14 Renal artery 
angiography is used in a similar fashion as coronary 
angiography, and is useful for an accurate analysis of 
anatomy and also as an adjunctive tool in the evalua-
tion of the results of interventions in this territory 
by means of quantitative angiography. In the present 
study, accurate renal angiographies were performed, 
with appropriate angles for better visualization of the 
renal arteries. The estimates applied in the initial tests 
were carefully repeated at the six-month follow-up in 
all patients involved in the study. The analyzes were 
interpreted with the aid of a contemporary program, 
QAngio XA, version 7.3. Measurements of maximum 
diameters in the proximal, middle, and distal seg-
ments of each renal artery before and 6 months after 
percutaneous RSD were performed. These procedures 
allowed us to assess the changes that took place, by 
comparing the averages of these measures.
The evaluation of sympathetic activity can be 
obtained directly by microneurography, usually of the 
TABLE 1 
Baseline characteristics of patients undergoing 
quantitative renal angiography before and 6 months 
after renal sympathetic denervation
Characteristic n = 13
Age, years 49 ± 10
Female, n (%) 11 (84.6)
Diabetes mellitus, n (%) 4 (30.7)
Dyslipidemia, n (%) 10 (76.9)
Smoking, n (%) 0
Prior myocardial infarct, n (%) 1 (7.6)
Previous stroke, n (%) 0
Peripheral arterial disease, n (%) 0
Family history of cardiovascular disease, 
n (%)
4 (30.7)
Figure 2 – Left, quantitative angiography measured at three points of the right renal artery, generating a report (right) in which the mean of diameters 
was calculated automatically by the program QAngio XA, version 7.3.
Armaganijan et al. 
Quantitative Renal Angiography After RSD
Rev Bras Cardiol Invasiva. 
2014;22(2):155-60
159
fibular nerve, and indirectly by means of norepinephrine 
spillover.9 Although available, these methods are not 
routinely adopted in clinical practice, due to limitations 
in their implementation. 
The development of microneurography, in which 
the neural activity can be recorded directly by means of 
microelectrodes inserted percutaneously into a peripheral 
nerve in humans, has provided valuable information on 
the control of sympathetic outflow to the muscle. This 
method allows for measuring the postganglionic efferent 
sympathetic nerve traffic to skeletal muscles, the so-called 
muscle sympathetic nerve activity (MSNA). The MSNA in 
different pathologies has expanded the knowledge about 
the functioning of the SNS. Although the quantification of 
MSNA is still largely limited to measures of frequency and 
incidence of bursts (bursts/min and bursts/100 heartbeats, 
respectively), the development of unit records of MSNA has 
provided more detailed information on the operation the 
SNS.15 In healthy subjects, MSNA is activated by decreases 
in cardiac filling pressure, exercise, hypoxia, hypercapnia, 
hyperpnoea, and sleep disorders, and is inhibited by lung 
inflation. Among the main clinical applications of sym-
pathetic microneurography, the authors must emphasize 
the elucidation of the neural mechanisms of control of 
SAH and of thermoregulation. Despite obtaining direct 
measures of sympathetic activity (with the result that 
sympathetic microneurography is regarded as the gold 
standard), this technique has specific limitations, such as 
training and experience of the researcher, critical to the 
acquisition of high quality signals; reliance of the bursts’ 
amplitude relative to the position where the electrodes are 
applied; and the fact that the measure of MSNA in skel-
etal muscle may not reflect changes in renal and cardiac 
sites. Furthermore, this is a painful, time-consuming, and 
impractical method for use in the clinical environment, 
more suitable for research purposes.16
Historically, the methods used to measure changes 
of SNS in humans have consisted of determinations of 
norepinephrine, the primary neurotransmitter released 
from sympathetic postganglionic nerve endings. Today, 
the measurement of the excretion of this neurotransmitter 
Figure 3 – Quantitative angiography at right renal artery. Left, before percutaneous renal sympathetic denervation with a mean of proximal/middle 
third/distal diameters of 4.42 mm. Right, 6 months after the procedure, showing increase in mean diameters to 5.64 mm.
Figure 4 – Change in the maximum diameters of the renal arteries, 
6  months after percutaneous renal sympathetic denervation (RSD).
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in urine is a method into disuse as a test of sympathetic 
activity, while plasma concentration assays, although 
widely used yet, have two important limitations. The first 
of them is that these tests do not provide information on 
regional sympathetic function, and it is known that the 
sympathetic responses exhibit regional differences that 
can only be detected by techniques accessing organ-
specific sympathetic function. The second limitation is 
that the plasma norepinephrine concentration depends 
not only of the sympathetic tone and the amount re-
leased, but also of its extraction from plasma.17
The overflow of norepinephrine (spillover) toward 
plasma, based on the dilution of radiotracers, is one 
of the safest ways of assessing regional sympathetic 
function. Renal norepinephrine spillover consists of the 
administration of the tritium-marked neurotransmitter at 
a known concentration, accompanied by the collection 
of blood samples from renal veins.18 This is a complex 
method, with little application in clinical practice.
Therefore, the authors believe that, if properly 
performed by experienced operators and with a care-
ful attention to all the recommendations already well 
established, quantitative angiography of renal arteries 
can be a practical tool, easy to implement and of low 
cost, which will allow a better understanding of the 
results of percutaneous RSD.
Limitations
This study has limitations, for instance, the small 
sample size, as well as the inherent limitations of 
observational studies; in particular, the non-use of 
established methods of measurement of sympathetic 
activity for comparison with quantitative angiography.
CONCLUSIONS
The results of this analysis illustrate the significant 
increase in diameter of the renal arteries after a renal 
sympathetic denervation procedure, probably due to the 
increase of renal blood flow and decreased vasocon-
striction, both as a result of blockage or reduction of 
sympathetic activity. Randomized controlled trials are 
needed to consolidate these observations.
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